ARCA biopharma to Present at 27th Annual JPMorgan Healthcare ...(d on developing and commercializing gene...)

Date:1/8/2009

d on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate, Gencaro(TM) (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro. The New Drug Application for approval of Gencaro for the indication of chronic heart failure, including the proposed brand name, is currently under review by the U.S. Food and Drug Administration. The companion genetic test for Gencaro is in development by ARCA's partner, Laboratory Corporation of America. For more information please visit http://www.arcabiopharma.com.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor which has completed Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and NU206, a Wnt pathway modulator in Phase 1 development for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at its website at http://www.nuvelo.com or by phoning 650-517-8000.

Forward-looking statements

This press release conta
'/>"/>

SOURCE ARCA biopharma, Inc. and Nuvelo, Inc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma
2. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
3. Helix BioPharma Announces Q1 2009 Financial Results
4. McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries
5. ProMetic signs $35 M Long-term Supply Agreement with European Biopharmaceutical company
6. XTL Biopharmaceuticals Implements Restructuring Plan
7. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
8. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
9. MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)
10. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
11. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission